Cannabis Law Report

DECEMBER 26, 2021

The patent relates to improved technology for detection and maintenance of the optimal therapeutic psychedelic state, which Entheon intends to study through the monitoring of electroencephalogram (EEG) biomarkers in order to optimize the treatment of neuropsychiatric conditions. US Provisional Patent Filed. About Entheon Biomedical Corp.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

JANUARY 24, 2022

Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. His deep expertise across clinical development and related functions makes him a tremendous and timely addition to our team,” said Anthony Johnson, M.D., CAMBRIDGE, Mass.–(BUSINESS

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

JANUARY 12, 2022

Through the partnership, Maya’s Real World Evidence Platform will be one of the core services offered to the association’s members when it officially launches in Q4 of 2022. We don’t believe safety and access are opposing polarities that must be constantly balanced.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] Clinical Trials and Human Subject Protections. Trial of Psilocybin Versus Escitalopram for Depression , 384 New England J.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

OCTOBER 9, 2021

Under HB 1959 , which was formally filed with 19 cosponsors on Wednesday, the state Department of Health would authorize at least two entities to “plant, grow and cultivate natural psilocybin mushroom product solely for use in the clinical studies of psilocybin.”. Session of 2021 – 2022 Regular Session. House of Representatives.

Therapy 52

Therapy Clinical Trials Treatment Legislation 52

Cannabis Law Report

NOVEMBER 16, 2021

Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging. Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Chapman continued.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

FEBRUARY 28, 2022

20 February 2022. Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. Essay by I. war on drugs.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

SEPTEMBER 23, 2022

The continued criminalization of all drugs and the people who use them increases harms to public health and safety. MAPS is sponsoring the most advanced psychedelic therapy research in the world: Phase 3 clinical trials of MDMA-assisted therapy for PTSD. September 1, 2022.

Decriminalization 52

Decriminalization Advocacy Research and Development Education 52

Cannabis Law Report

DECEMBER 2, 2021

These recommendations will be sent to the Oregon Health Authority (OHA) for consideration during formal rulemaking, with hearings scheduled from February 14 to February 25, 2022. Safety, Ethics and Responsibilities of a Psilocybin Facilitator (10 Hours). Psilocybin Pharmacology, Neuroscience, and Clinical Research (12 Hours).

Law 52

Law Programs Therapy Education 52

Veriheal

MAY 16, 2022

Researchers working at the University of Arizona College of Medicine in Tucson have refined a method of ketamine use in the treatment of Parkinson’s disease (PD). Specifically, the group focused on ketamine’s ability to relieve the side effects of a common treatment called Levodopa.

Research and Development 19

Research and Development Treatment Clinical Trials Patients 19

The Cannigma

DECEMBER 12, 2022

Scientists are hopeful that psychedelics might have more of a curative effect when it comes to mental health than many existing treatment options; meaning that unlike most psychiatric medications, psychedelics may be able to prompt long-term changes to our mental state with only a few doses. Are psychedelics safe?

History 119

History Microdosing Research and Development Clinical Trials 119

Cannabis Law Report

OCTOBER 29, 2021

(NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year. The primary endpoint of this Phase 1 trial was safety and tolerability. We may not receive regulatory approval for our products, or trials.

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Cannabis Law Report

DECEMBER 9, 2021

The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch. DENVER, Dec. DENVER, Dec.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Available at: [link] Accessed October 17, 2022. February 2, 2022.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

APRIL 13, 2022

Apr 12, 2022, 07:00 ET. Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Transaction expected to close in June 2022 , following anticipated shareholder approval. Numinus Wellness Inc. .

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

The Cannigma

JANUARY 13, 2023

While migraines are a commonly reported condition by patients in cannabis studies, there is little clinical research on how cannabis can influence migraine pain. Daily cannabis consumption was an effective treatment for 85% of participants. headaches per month. Ethan Russo details the historical use of cannabis for migraines.

Terpenes 132

Terpenes Strains THC Treatment 132

Cannabis Law Report

DECEMBER 28, 2021

We recently announced that we anticipate commencing our initial human trial for Epoladerm™ in the second quarter of 2022. We are on track to add accomplishments in 2022 and I remain confident that we have the significant financial strength to continue advancing our pipeline,” concluded Mr. Mack.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

NOVEMBER 26, 2021

Corporate and Clinical Development Highlights Include: Completed Patient Enrollment in Phase III Psoriasis Study – The Phase III Comfort™ study completed patient enrollment. Topline results are expected in Q1 2022. Financial Results. Revenues for the nine months ended September 30, 2021 were $0.65

Clinical Trials 52

Clinical Trials Research and Development Treatment Data 52

The Cannigma

FEBRUARY 1, 2023

To date, very few human clinical trials have been conducted to assess the effectiveness of THC or CBD in treating cancer. 7 The use of cannabis as a cancer treatment was popularized by Rick Simpson, a medical cannabis advocate. GBM is a rare but aggressive brain cancer with very limited treatment options.

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145